O ral anticoagulant therapy is essential for the treatment and prevention of many thromboembolic disorders. Since anticoagulants can cause serious adverse events, 1-3 physicians monitor the international normalized ratios of patients taking these drugs to ensure that their ratios fall within a target range.
thromboembolic events. We included studies if they reported the number of hemorrhages or thromboemboli that occurred, along with the corresponding person-years of observation in at least 3 ranges of international normalized ratios (< 2, 2-3 and > 3). We included studies irrespective of therapeutic indication, target range of international normalized ratios, duration of anticoagulant use, type of anticoagulant used or treatment setting.
Data abstraction and study quality
We abstracted data for groups of patients who received anticoagulants alone. We excluded data for patients who received antiplatelet medications with their anticoagulants because their risk of hemorrhagic events was significantly higher than that of patients who received anticoagulants alone. 8, 9 Two of us (N.O. and A.J.) independently abstracted the data, and we resolved discrepancies by committee. We abstracted data presented in graphs by using previously described methods, 10 which recommend enlarging graphics.
To determine the overall relative risk (RR) and absolute risk of hemorrhage or thromboemboli by range of international normalized ratios, we required data for both the events and the person-years of observation. First, we abstracted the number of hemorrhages and thromboemboli that occurred in each range of ratios, along with the types of events captured and the criteria required for each. If studies reported events by severity, we included all but those classified as "minor." Second, we abstracted the person-years of observation for each range of ratios. We then grouped events and person-years of observation by range of international normalized ratios (i.e., < 2, 2-3, 3-5 and > 5). These 4 ranges reflect the most common categorizations in the eligible studies. We could not analyze the international normalized ratio as a continuous variable since we did not have access to the primary data for each study. We assigned to the "3-5" range the events and corresponding person-years of observation reported for ratios that exceeded 3, that fell between 3 and 4.5 or that fell between 3 and 5. Similarly, we assigned to the "> 5" range the data reported for ratios that exceeded 4.5 or 5.
We abstracted additional information to gauge the internal validity of eligible studies. For the number of events reported in each range of international normalized ratios, we abstracted the criteria for assigning events to a particular range, the number of events that were not assigned to a range, and the followup methods used to identify events (because the number of events identified is dependent on the intensity of patient follow-up [11] [12] [13] ). For the person-years of observation at reported ranges, we determined what method of imputation was used to calculate person-years of observation (since some imputation methods are superior to others 14 ). We also ascertained whether measurements taken outside of the study centre were captured (since failure to capture all ratios results in inaccurate estimates of the patient observation time at reported ranges 14 ).
Statistical analysis
For each study, we calculated the hemorrhagic and thromboembolic rates specific to 4 ranges of international normalized ratios based on the number of events at each ratio range divided by the person-years of observation assigned to that range. Using the range of 2-3 as the reference category, we calculated the relative and absolute risks of hemorrhagic, thromboembolic and combined events for ranges less than 2, 3-5 and greater than 5. We used negative binomial regression with generalized estimating equation methodology because of the overdispersion that we observed when using Poisson distribution. 15 Generalized estimating equation methodology was used to account for clustering of rates for the different ranges of ratios within each study. [16] [17] [18] We used an exchangeable correlation structure in the generalized estimating equation model, which assumed that the correlations were equal across all measurements within the independent studies. 16 We weighted the studies by the logarithm of their total person-years of observation assigned to international normalized ratios. We calculated the 95% confidence intervals (CIs) for the absolute and relative risks using critical values based on the Poisson distribution. 19 We expected the absolute risk of thromboembolic events to vary by patient population, with the risks possibly being higher among patients with atrial fibrillation or valvular heart disease than among other patients taking anticoagulants. Therefore, we recalculated rates of thromboembolic events after grouping studies based on the most common indication for anticoagulation. We classified studies in which more than 70% of patients had atrial fibrillation or valvular heart disease as having a focus on these diseases. We used the BreslowDay test to measure heterogeneity of event rates among the studies.
Sensitivity analysis
We conducted 5 sensitivity analyses to examine the robustness of the results of our generalized estimating equation model. First, few nonintracranial hemorrhages secondary to warfarin lead to death or disability, whereas intracranial hemorrhages have an impact on health that is similar to ischemic strokes. 20, 21 For this reason, we conducted a subanalysis of studies that limited their analyses to severe hemorrhagic events, including intracranial hemorrhages and fatal hemorrhages. [21] [22] [23] Second, it is possible that the indication for oral anticoagulant therapy could influence results. Therefore, we conducted a subanalysis of studies involving only patients who required anticoagulation for atrial fibrillation, venous thromboembolic disease or atherosclerotic disease, including cerebrovascular disease, coronary artery disease and peripheral vascular disease.
Third, 6 of the eligible studies reported a maximum range of international normalized ratios greater than 3. [24] [25] [26] [27] [28] [29] For our base analysis, we grouped the person-years of observation and events from these studies in the ratio category of 3-5. We repeated our analysis after imputing the person-years of observation and the number of events that occurred when the ratio exceeded 5. We used the studies with complete information to determine the mean proportion of events and personyears of observation that actually occurred at a ratio greater than 5. To impute data for the 6 eligible studies, we multiplied the mean proportion of events and person-years of observation by the number of events and time actually reported for the "> 3" range.
Fourth, we conducted a sensitivity analysis that excluded studies containing the greatest number of events to investigate whether the results changed after their removal. Finally, we looked for possible interactions between the association of the international normalized ratio and event risk with potential confounders, including the indication for oral anticoagulant therapy, the type of anticoagulant prescribed and the presence of cancer or renal failure.
Results

Study identification and selection
Our search returned 2763 citations. Of those, we retrieved 263. We excluded 246 studies because they did not report the number of events or person-years of observation for 3 or more ranges of international normalized ratios, included previously reported data or reported ranges that did not fit into the 4 ranges in our study. 30, 31 We identified 2 additional studies by manually searching references on the Science Citation Index (Figure 1) .
We included 19 studies published between 1992 and 2007 in our analysis 6, [21] [22] [23] [24] [25] [26] [27] [28] [29] [32] [33] [34] [35] [36] [37] [38] [39] [40] (Table 1) . Of these, 14 reported both hemorrhagic and thromboembolic events, 6, 21, 23, 25, [27] [28] [29] [32] [33] [34] [35] [36] [37] 39 3 reported only hemorrhagic events, 22, 38, 40 and 2 reported only thromboembolic events. 24, 26 Half were retrospective cohort studies and two-thirds (68%) were community-based studies. Warfarin was the only anticoagulant used in 9 of the studies. Six of the studies included patients with various indications for oral anticoagulant therapy, including atrial fibrillation, venous thromboembolism and ischemic heart disease.
The 19 studies involved a total of 80 713 patients and accounted for 98 900 person-years of observation. The number of patients in each study ranged from 55 24 to 42 451. 22 Overall, 35 514 (44%) of the patients were female. Study characteristics are outlined in Table 1 and Appendix 2, available online at www.cmaj.ca/cgi/content/full/179/3/235/DC2.
Study quality
The type of events captured and the criteria required for each varied somewhat among the studies (Appendix 3, available online at www.cmaj.ca/cgi/content/full/179/3/235/DC2). We considered hemorrhagic events to be clinically overt hemorrhaging that resulted in hospital admission, blood transfusion or surgery; however, 2 studies restricted events to uncommon hemorrhagic events, including intracranial hemorrhages 21 and fatal hemorrhages. 22 Thromboembolic events most commonly included strokes, myocardial infarction and systemic emboli.
Of the 19 included studies, 13 reported ranges of international normalized ratios that fit into the 4 categories in our study. 6, [21] [22] [23] [32] [33] [34] [35] [36] [37] [38] [39] [40] The remaining studies reported ranges that fit only into 3 categories because their maximum range was a ratio greater than 3. [24] [25] [26] [27] [28] [29] Studies differed in the methods used to identify hemorrhagic and thromboembolic events and assign them to ranges of international normalized ratios. To identify events, 12 studies used follow-up visits, 23, [25] [26] [27] [28] [32] [33] [34] [36] [37] [38] [39] 4 used medical record review alone, 24, 29, 35, 40 and 3 used administrative databases, including those for billing claims, 21 discharge abstracts 6 and deaths. 22 To assign events to a range, 4 studies used only ratios measured at the time of the event. 22, 24, 28, 39 If ratios at the time of the events were unavailable, 15 studies assigned events to a range using previous measurements, taken from 2 days 32 to as many as 28 days 36,39 before the event. 6, 21, 23, 25, 26, 29, [32] [33] [34] [35] [36] [37] [38] [39] [40] Half of the studies excluded at least one event because they could not be assigned to a range.
Details regarding the person-years of observation also varied among the studies. Fifteen studies used linear interpolation (i.e., placing a line between determined values) to impute values for days between measured ratios. 6, 21, [23] [24] [25] [26] 28, 29, [32] [33] [34] [35] 37, 38, 40 The remaining studies used equidivision 27, 36 (i.e., assigning the first ratio to the first half of the period between measured ratios and assigning the second ratio to the last half of the period) or did not report an imputation method. 22, 24 Finally, only 3 studies captured all measures of ratios (including those measured outside of the regular monitoring clinic). 22, 33, 37 International normalized ratios and event rates Absolute rates of hemorrhagic and thromboembolic events differed greatly among the studies (Appendix 4, available online at www.cmaj.ca/cgi/content/full/179/3/235/DC2). Rates of hemorrhagic events in 13 studies increased with higher international normalized ratios. Articles identified through database search n = 2763
Articles retrieved for more detailed evaluation n = 263
Excluded n = 2500
• Neither title nor abstract indicated that patients were taking anticoagulants or that hemorrhagic or thromboembolic events were captured
Excluded n = 246
• Patient observation time and events not reported for specific ranges of international normalized ratios n = 242 • Patient observation time and events could not be grouped into our study's ranges of international normalized ratios n = 2 linear association, where rates of hemorrhagic events associated with ratios less than 2 exceeded the rates associated with ratios between 2 and 3. 25, 33, 34, 38 Rates of thromboembolic events in 9 studies increased with lower ratios. [24] [25] [26] [27] [28] [29] 33, 37, 39 Seven studies reported a curvilinear association, where rates of thromboembolic events increased when ratios exceeded 5. 6, 21, 23, 32, 33, 35, 36 Research Van Walraven et al. 6 Kearon et al. 28 EAFT 36 Azar et al. 39 Palareti et al. 38 Casais et al. 40 Hutten et al. 25 Tangelder et al. 34 Torn et al. 35 Yasaka et al. 27 Andersen et al. 37 Poli et al. 33 Cheung et al. 29 Chimowitz et al. 32 Hylek et al. 21 Oden et al. Our negative binomial regression model showed that the overall relative risk of hemorrhage increased significantly as international normalized ratios increased ( Figure 2 , Table 2 ; Appendix 5, available online at www.cmaj.ca/cgi/content/full /179/3/235/DC2). Compared with ratios of 2-3, the relative risk of hemorrhagic events (and 95% CIs) was 2.7 (1.8-3.9; p < 0.01) for ratios of 3-5 and 21.8 (12.1-39.4; p < 0.01) for ratios greater than 5. These results translated to absolute risks (and 95% CIs) of 3.7%/yr (2.2%-6.3%) for ratios of 3-5 and 30.1%/yr (14.9%-60.9%) for ratios greater than 5, compared with a rate of 1.4%/yr (0.9%-2.3%) for ratios of 2-3.
The risk of thromboemboli increased significantly with low international normalized ratios ( Figure 3 , Table 2 ; Appendix 5). Compared with ratios of 2-3, the relative risk of thromboemboli (and 95% CI) associated with ratios less than 2 was 3.5 (2.8-4.4; p < 0.01). The risk of thromboemboli also increased when ratios exceeded 5 (RR 2.6, 95% CI 1.3-5.1; p < 0.01). Overall, the absolute risk (and 95% CI) of thromboembolic events was 2.6%/yr (1.8%-3.6%) for ratios of 2-3, compared with 9.0%/yr (6.1%-13.4%) for ratios less than 2 and 6.6%/yr (3.2%-13.9%) for ratios greater than 5. The risk of thromboembolic events for studies that focused on patients with atrial fibrillation or valvular heart disease are given in Table 2 .
After we combined hemorrhagic and thromboembolic events, our results showed that an international normalized ratio of 2-3 was significantly safer than all other ranges of ratios ( Figure 4, Appendix 5) . The model showed a strong curvilinear association between the ratio and the combined risk of hemorrhage and thromboemboli (Table 2) . We found that a ratio of 2-3 had the lowest absolute risk of events (RR 4.3%/yr, 95% CI 3.0%-6.3%). The next safest ratio was 3-5 (RR 1.8, 95% CI 1.2-2.6). The risk of an event was lower at this ratio than at a ratio less than 2 (RR 2.4, 95% CI 1.9-3.1) but was not statistically significant (p = 0.10).
The results of the Breslow-Day test for heterogeneity among studies for both types of events were significant (p < 0.001). This finding indicated varying interstudy rates of hemorrhagic and thromboembolic events that exceeded what would reasonably be expected by chance.
Sensitivity analyses
We obtained results similar to those mentioned earlier when we limited our analysis to studies that included only intracranial or fatal hemorrhages (Appendix 6, available online at www.cmaj.ca/cgi/content/full/179/3/235/DC2). Our results showed a curvilinear association between anticoagulation intensity and risk of event, with a ratio of 3-5 being the safest nontherapeutic range. In fact, we found that the relative risk associated with a ratio of 3-5 was significantly lower than that for a ratio less than 2. Our results did not change significantly when we limited our analysis to studies that involved only patients with atherosclerotic disease, atrial fibrillation or venous thromboembolism (Appendix 7, available online at www.cmaj.ca/cgi/content/full/179/3/235/DC2).
Our model results did not change significantly when we imputed data for ratios greater than 5 for the 6 studies that did not report the number of events and person-years of observa- tion for this range. Our model results were also robust when we excluded the studies reporting the most events. The relation between the international normalized ratio and the risk of an event was not significantly influenced by the indication for oral anticoagulant therapy, the type of anticoagulant prescribed, or the presence of cancer or renal failure (p < 0.05).
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Interpretation
We found a strong association between anticoagulation intensity and the risk of hemorrhagic and thromboembolic events. The risk of hemorrhage significantly increased when the international normalized ratio exceeded 3. The risk of thromboemboli was greatest when the ratio was below 2. Overall, patients were safest with a ratio of 2-3. Numerous studies have shown that patients spend more time with ratios below than above the therapeutic range. 6, 7 This could be partly attributable to an overestimated risk of hemorrhage associated with oral anticoagulant use. Van Walraven et al. 6 Tangelder et al. 34 Poli et al. 33 Cheung et al. 29 EAFT 36 Yasaka et al. 27 Torn et al. 35 Chimowitz et al. 32 Hutten et al. 25 Azar et al. 39 Hylek et al. a survey conducted by Gross and colleagues 41 showed that physicians' estimates of annual rates of intracranial hemorrhage associated with the use of warfarin were more than 10 times higher than those based on the literature. 41 When both hemorrhagic and thromboembolic events are considered, our data showed that patients were safer with a ratio slightly above, rather than below, the therapeutic range of 2-3. Physicians should be aware of this finding and should adjust their clinical practices accordingly by aggressively correcting subtherapeutic ratios and avoiding overreaction to ratios that narrowly exceed 3. More extensive use of computer-based algorithms for does adjustment of anticoagulants could help avoid systemic underanticoagulation. [42] [43] [44] [45] [46] We found that the relative risk of thromboembolic events increased significantly when the international normalized ratio exceeded 5. This reflects the curvilinear association between ratio levels and risk of thromboemboli that we identified in 7 of 16 studies included in our analysis. This curvilinear association could be attributable to high-risk subpopulations of patients, including those with neoplasia, valve replacements and thrombophilic syndromes. Such patients could have higher target ratios, and thus a greater risk of ratios exceeding 5, which, along with a greater risk of thromboemboli in such patients, might explain the curvilinear association that we observed.
Our review has limitations at the study level. First, the number of events at reported ranges of international normalized ratios could be biased since most of the studies failed to assign all events to ranges. Second, the person-years of observation at reported ranges may have been inaccurate. Although linear imputation of ratios between actual measures is an industry standard, 14, 47 it has some error. 14, 48 It is unlikely that patients' international normalized ratios always vary linearly between actual measures. In addition, 2 studies used imputation methods with error exceeding that of linear interpolation. Only 2 studies captured ratios that were measured outside of the study centre.
Our study also has limitations at the review level. We may have missed eligible studies despite our extensive literature search. More importantly, the studies included in our review were somewhat limited by incomplete reporting. We excluded 8 studies [49] [50] [51] [52] [53] [54] [55] [56] that reported event rates specific to ranges of ratios but that did not provide the number of events and person-years of observation in discrete ranges. Although unlikely, the inclusion of these studies might have changed our results. For example, the relative and absolute risk estimates may have been more precise. Second, we found heterogeneity among the 19 studies, which was not surprising since heterogeneity is expected when observational studies are included in meta-analyses. 57 Despite the interstudy heterogeneity, we proceeded with the meta-analysis because the generalized estimating equation methodology clusters ranges of international normalized ratios within studies. Such clustering of outcomes takes study heterogeneity into account. Third, we were able to report the absolute and relative risks of events for only 4 clinically relevant ranges of international normalized ratios. Narrower ranges of ratios in our model may have given more precise results. However, our use of 4 ranges is related to how the original data were reported. Finally, since we were dealing with study-level variables, our study had limited power to detect the influence of patient-level variables on the association between anticoagulant intensity and risk of events.
Our study showed a strong and robust association between anticoagulation intensity and clinically relevant outcomes. For the most common indications for anticoagulation, maximizing the length of time at which a patient's international normalized ratio is in the therapeutic range of 2-3 should minimize the risk of both hemorrhagic and thromboembolic events. Avoiding systematic underanticoagulation will also improve patient outcomes.
Our results also have important implications for researchers. They show that researchers must continue to evaluate interventions, including anticoagulation clinics, 47, 58, 59 patient self-management [60] [61] [62] and telephone communication systems, 63 that increase the amount of time at which patients' international normalized ratios are within the therapeutic range.
